MYNZ Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (9 geg. 2024 @ 23:00):

Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics...

Stats
Dzisiejszy wolumen	171 482
Średni wolumen	105 662
Kapitalizacja rynkowa	14.42M
EPS	$0 ( 2024-04-08 )
Następna data zysków	( $-0.310 ) 2024-05-21
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.410
ATR14	$0.00600 (0.92%)

Wolumen Korelacja

Długi: -0.14 (neutral)

Krótki: -0.61 (weak negative)

Signal:(46.694) Neutral

Mainz Biomed B.V. Korelacja

10 Najbardziej pozytywne korelacje
BNDW	0.809
GLPI	0.807
SOHO	0.805
EWZS	0.801
TLT	0.801

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Mainz Biomed B.V. Korelacja - Waluta/Towar

0.09
( neutral )

-0.32
( neutral )

0.00
( neutral )

-0.60
( weak negative )

-0.51
( weak negative )

Mainz Biomed B.V. Finanse

Annual	2023
Przychody:	$895 479
Zysk brutto:	$509 659 (56.91 %)
EPS:	$-1.620

FY	2023
Przychody:	$895 479
Zysk brutto:	$509 659 (56.91 %)
EPS:	$-1.620

FY	2022
Przychody:	$529 877
Zysk brutto:	$182 151 (34.38 %)
EPS:	$-1.870

FY	2021
Przychody:	$577 348
Zysk brutto:	$177 622 (30.77 %)
EPS:	$-1.620

Financial Reports:

No articles found.

Mainz Biomed B.V.

Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.